Richard Mulligan - Mar 2, 2023 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role
Head of SanaX, Director
Signature
/s/ Bernard J. Cassidy, Attorney-in-Fact for Richard Mulligan
Stock symbol
SANA
Transactions as of
Mar 2, 2023
Transactions value $
$0
Form type
4
Date filed
3/3/2023, 03:32 PM
Previous filing
Jun 28, 2022
Next filing
May 19, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SANA Stock Options (Right to Buy) Award $0 +200K $0.00 200K Mar 2, 2023 Common Stock 200K $3.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the underlying shares on March 2, 2024 and in 36 equal monthly installments thereafter.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney